Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin

International Journal of Cancer

Volumn 125, Issue 10, 2009, Pages 2316-2322

  Kim, Ayako ^a,b   Enomoto, Takayuki ^a   Serada, Satoshi ^b   Ueda, Yutaka ^a   Takahashi, Tsuyoshi ^a,b   Ripley, Barry ^b   Miyatake, Takashi ^a   Fujita, Masami ^a   Lee, Chun Man ^c   Morimoto, Koji ^a   Fujimoto, Minoru ^b   Kimura, Tadashi ^a   Naka, Tetsuji ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^c OSAKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Annexin A4; Chemoresistance; Clear cell carcinoma of the ovary

Indexed keywords

CARBOPLATIN; LIPOCORTIN 4;

ARTICLE; CLEAR CELL CARCINOMA; CONTROLLED STUDY; GEL ELECTROPHORESIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; ANNEXIN A4; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARBOPLATIN; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 70349880530     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24587     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 2008;99:653-658
3. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004;3:355-366 (Pubitemid 38702089)
4. Rapkiewicz AV, Espina V, Petricoin EF, III, Liotta LA. Biomarkers of ovarian tumours. Eur J Cancer 2004;40:2604-2612
5. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584-2589 (Pubitemid 30331967)
6. Pectasides D, Pectasides E, Psyrri A, Economopoulos T. Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist 2006;11:1089-1094
7. Kaetzel MA, Hazarika P, Dedman JR. Differential tissue expression of three 35-kDa annexin calcium-dependent phospholipid-binding proteins. J Biol Chem 1989;264:14463-14470 (Pubitemid 19214282)
8. Zanotti G, Malpeli G, Gliubich F, Folli C, Stoppini M, Olivi L, Savoia A, Berni R. Structure of the trigonal crystal form of bovine annexin IV. Biochem J 1998;329:101-106 (Pubitemid 28022296)
9. Kaetzel MA, Mo YD, Mealy TR, Campos B, Bergsma-Schutter W, Brisson A, Dedman JR, Seaton BA. Phosphorylation mutants elucidate the mechanism of annexin IV-mediated membrane aggregation. Biochemistry 2001;40:4192-4199 (Pubitemid 32280457)
10. Hill WG, Kaetzel MA, Kishore BK, Dedman JR, Zeidel ML. Annexin A4 reduces water and proton permeability of model membranes but does not alter aquaporin 2-mediated water transport in isolated endosomes. J Gen Physiol 2003;121:413-425
11. Sohma H, Creutz CE, Gasa S, Ohkawa H, Akino T, Kuroki Y. Differential lipid specificities of the repeated domains of annexin IV. Biochim Biophys Acta 2001;1546:205-215 (Pubitemid 32217817)
12. Piljic A, Schultz C. Annexin A4 self-association modulates general membrane protein mobility in living cells. Mol Biol Cell 2006;17:3318-3328 (Pubitemid 43993530)
13. Kaetzel MA, Chan HC, Dubinsky WP, Dedman JR, Nelson DJ. A role for annexin IV in epithelial cell function. Inhibition of calcium-activated chloride conductance. J Biol Chem 1994;269:5297-5302 (Pubitemid 24239525)
14. Han EK, Tahir SK, Cherian SP, Collins N, Ng SC. Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br J Cancer 2000;83:83-88 (Pubitemid 30352721)
15. Morita A, Miyagi E, Yasumitsu H, Kawasaki H, Hirano H, Hirahara F. Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma. Proteomics 2006;6:5880-5890 (Pubitemid 44764024)
16. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996;68:850-858 (Pubitemid 26101214)
17. Ikuta K, Takemura K, Sasaki K, Kihara M, Nishimura M, Ueda N, Naito S, Lee E, Shimizu E, Yamauchi A. Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells. Biol Pharm Bull 2005;28:707-712 (Pubitemid 40879942)
18. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360:505-515
19. Tammela J, Geisler JP, Eskew PN, Jr, Geisler HE. Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma. Eur J Gynaecol Oncol 1998;19:438-440 (Pubitemid 28479390)
20. O'Brien ME, Schofield JB, Tan S, Fryatt I, Fisher C, Wiltshaw E. Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol 1993;49:250-254 (Pubitemid 23170001)
21. Raynal P, Pollard HB, Srivastava M Cell cycle and post-transcriptional regulation of annexin expression in IMR-90 human fibroblasts. Biochem J 1997;322:365-371 (Pubitemid 27116558)